An Educational Resource by
Women's Cancer Initiative - Tata Memorial Hospital
Surgical treatment of women with breast cancer and a BRCA1 mutation: An international analysis of the impact of bilateral mastectomy on survival
Contralateral breast cancer risk in patients with breast cancer and a germline-BRCA1/2 pathogenic variant undergoing radiation
Speaker : Dr. Veda Padma Priya
Sentinel Lymph Node Biopsy vs No Axillary Surgery in Patients With Small Breast Cancer and Negative Results on Ultrasonography of Axillary Lymph Nodes The SOUND Randomized Clinical Trial
Lymph Node Positivity of Axillary Reverse Mapping Lymph Nodes at the Time of Axillary Lymph Node Dissection: Two-Site Prospective Trial
Speaker : Dr. Poovamma CU
Radiotherapy to regional nodes in early breast cancer: an individual patient data meta-analysis of 14 324 women in 16 trials
Radiotherapy or Surgery of the Axilla After a Positive Sentinel Node in Breast Cancer: 10-Year Results of the Randomized Controlled EORTC 10981-22023 AMAROS Trial
Speaker : Dr. Dodul Mondal
Five-year outcomes of the IDEA trial of endocrine therapy without radiotherapy after breast-conserving surgery for postmenopausal patients age 50-69 with genomically-selected favorable Stage I breast cancer
Development and Validation of a Genomic Prole for the Omission of Local Adjuvant Radiation in Breast Cancer
Speaker : Dr. Joy Ghose
Overview of axillary treatment in early breast cancer: patient-level meta-analysis of long-term outcomes among 20,273 women in 29 randomised trials
Mammographic surveillance in early breast cancer patients aged 50 years or over: results of the Mammo-50 non-inferiority trial of annual versus less frequent mammography
Speaker : Dr. Priyanka Singh
Panel Discussion on Key Abstracts/Publication in Loco-Regional Breast Cancer
Moderator : Dr. Vedant Kabra
Panel Discussion on Key Abstracts/Publication in Loco-Regional Breast Cancer
Moderator : Dr. Sanjoy Chatterjee
Ecacy of Oral SERDs in the treatment of ER+, HER2 - metastatic breast cancer, a stratied analysis of the ESR1 wild type and mutant subgroups
Dynamics and type of ESR1 mutations under aromatase inhibitor or fulvestrant combined with palbociclib after randomization in the PADA-1 trial
Speaker : Dr. Mansi Sharma
Pooled ctDNA analysis of MONALEESA phase III advanced breast cancer trials
Randomized Phase II Trial of Endocrine Therapy With or Without Ribociclib After Progression on Cyclin-Dependent Kinase 4/6 Inhibition in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: MAINTAIN Trial
Speaker : Dr. Akash Jha
Invasive disease–free survival (iDFS) across key subgroups from the phase III NATALEE study of ribociclib (RIB) + a nonsteroidal aromatase inhibitor (NSAI) in patients (pts) with HR+/HER2- early breast cancer (EBC)
Ribociclib and endocrine therapy as adjuvant treatment in patients with HR+/HER2- early breast cancer: Primary results from the phase III NATALEE trial
Ribociclib (RIB) + nonsteroidal aromatase inhibitor (NSAI) as adjuvant treatment in patients with HR+/HER2? early breast cancer: nal invasive disease–free survival (iDFS) analysis from the NATALEE trial
Speaker : Dr. Shriniwas Kulkarni
Eects of ovarian ablation or suppression on breast cancer recurrence and survival: Patient-level meta-analysis of 14,993 premenopausal women in 25 randomized trials
Adding Ovarian Suppression to Tamoxifen for Premenopausal Women With Hormone Receptor-Positive Breast Cancer After Chemotherapy: An 8-Year Follow-Up of the ASTRRA Trial
Speaker : Dr. Bhavesh Poladia
Neoadjuvant chemotherapy combined with endocrine therapy for hormone receptor-positive breast cancer: A systematic review and meta-analysis
Adjuvant abemaciclib plus endocrine therapy for high-risk, HR+, HER2-, early breast cancer: results from a preplanned monarchE overall survival interim analysis, including 5-year ecacy outcomes
Speaker : Dr. Vindhya Vasini
PARSIFAL-LONG: Extended follow-up of hormone receptor-positive HER2-negative advanced breast cancer patients treated with fulvestrant and palbociclib vs. letrozole and palbociclib in the PARSIFAL study
Primary outcome analysis of the phase 3 SONIA trial (BOOG 2017-03) on selecting the optimal position of cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors for patients with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC)
Speaker : Dr. Kripa Bajaj
Capivasertib in Hormone Receptor–Positive Advanced Breast Cancer
Imlunestrant with or without everolimus or alpelisib, in ER+, HER2- advanced breast cancer (aBC): Results from the Phase 1a/b EMBER study
Speaker : Dr. Kripa Bajaj
Post-CDK 4/6 Inhibitor Therapy: Current Agents and Novel Targets in MBC
Speaker : Dr. Stephen K. L. Chia
Panel Discussion on Key Abstracts/Publication in ER+ve Breast Cancer
Moderator : Dr. Senthil Rajappa
Long-term outcomes of neoadjuvant immunotherapy plus chemotherapy in patients with early-stage triple-negative breast cancer: an extracted individual patient data and trial-level meta-analysis
Anthracycline-containing and taxane-containing chemotherapy for early-stage operable breast cancer: a patient-level meta-analysis of 100 000 women from 86 randomised trials
Speaker : Dr. Narmadha Rathinasamy
Randomized trial of xed dose capecitabine compared to standard dose capecitabine in metastatic breast cancer: The X-7/7 trial
BRCA-CRisk: A Contralateral Breast Cancer Risk Prediction Model for BRCA Carriers
Speaker : Dr. Deenadayalan T.
Patient characteristics and real-world outcomes in HER2 negative/ ER zero and ER low patients treated as triple-negative breast cancer in Sweden 2008-2020
Risk factors for the development of triple-negative breast cancer versus non-triple-negative breast cancer: a case-control study
Speaker : Dr. Sujay Srinivas
IO and IO combinations across all breast cancer subtypes are here to stay
Speaker : Dr. Shaheenah Dawood
Panel discussion on key abstracts in TNBC
Moderator : Dr. Ashish Bakshi
A randomized, open-label phase III trial evaluating low- dose vs standard-dose olanzapine with triple antiemetic therapy for prevention of highly emetogenic chemotherapy- induced nausea and vomiting in solid tumors (OLAnzaPiNE).
Ecacy and safety of mirogabalin for chemotherapy-induced peripheral neuropathy: a prospective single-arm trial (MiroCIP study)
Speaker : Dr. Mansi Shah
International Pooled Analysis of Leisure-Time Physical Activity and Premenopausal Breast Cancer in Women From 19 Cohorts
Vaginal Estrogen Therapy Use and Survival in Females With Breast Cancer
Speaker : Dr. Sushmita Rath
Randomized Trial of Exercise and Nutrition on Chemotherapy Completion and Pathologic Complete Response in Women With Breast Cancer: The Lifestyle, Exercise, and Nutrition Early After Diagnosis Study
Speaker : Dr. M. V. Chandrakanth
Pregnancy After Breast Cancer in Young BRCA Carriers: An International Hospital-Based Cohort Study
Interrupting Endocrine Therapy to Attempt Pregnancy after Breast Cance
Speaker : Dr. Rahul Kulkarni
Mepitel Film for the Prevention of Acute Radiation Dermatitis in Breast Cancer: A Randomized Multicenter Open-Label Phase III Trial
Association of Staphylococcus aureus Colonization With Severity of Acute Radiation Dermatitis in Patients With Breast or Head and Neck Cancer
Bacterial Decolonization for Prevention of Radiation Dermatitis: A Randomized Clinical Trial
Speaker : Dr. Chandrani Mallick
Recurrence-free survival following sentinel node-positive breast cancer without completion axillary lymph node dissection – rst results from the international randomized SENOMAC trial.
Local Recurrence After Breast Conserving Therapy in Patients with Multiple Ipsilateral Breast Cancer : Results from ACOSOG Z11102 (Alliance)
Speaker : Dr. Akshita Singh
Omitting Radiotherapy after Breast-Conserving Surgery in Luminal A Breast Cancer
Breast-Conserving Surgery with or without Irradiation in Early Breast Cancer
Speaker : Dr. Mansi Munshi
Proton FLASH Radiotherapy for the Treatment of Symptomatic Bone Metastases: The FAST-01 Nonrandomized Trial
Dose-escalated simultaneous integrated boost radiotherapy in early breast cancer (IMPORT HIGH): a multicentre, phase 3, non-inferiority, open-label, randomised controlled trial
Speaker : Dr. Sanjay M H
Eect of Peritumoral Inltration of Local Anesthetic Before Surgery on Survival in Early Breast Cancer
Impact of 18F-Labeled Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography Versus Conventional Staging in Patients With Locally Advanced Breast Cancer
Speaker : Dr. Purvi Thakkar
Hormonal Contraception and the Risk of Breast Cancer in Women of Reproductive Age: A Meta-Analysis
Global Stage Distribution of Breast Cancer at Diagnosis: A Systematic Review and Meta-Analysis
Speaker : Dr. Aditi Chaturvedi
Panel Discussion
Moderator : Dr. Geeta K , Dr. Anusheel Munshi